• About us
• Contact

Advertisement

Organisation › Details

Vifor Pharma AG

Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348). *

 

	Start	2011-02-22 existent
	Group	Vifor Pharma (Group)
	Industry	pharmaceutical
	Person	Zampieri, Gianni (Galenica Group 201702 CEO of Vifor Pharma)
	Person 2	Tulstrup, Søren (Hansa Biopharma 2018– CEO formerly Galenica + Shire + Santaris Pharma)
	Region	Glattbrugg ZH
	Country	Switzerland
	Street	61 Flughofstr.
	City	8152 Glattbrugg ZH
	Tel	+41-58-851-8000
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
		* Document for »About Section«: Vifor Pharma AG. (12/14/21). "Press Release: CSL Limited Announces Tender Offer to Acquire Vifor Pharma Ltd (ad hoc)". St. Gallen.
		Record changed: 2023-07-10

Advertisement

More documents for Vifor Pharma (Group)

• [1] T-Knife Therapeutics, Inc.. (1/5/22). "Press Release: T-knife Therapeutics Appoints Ronald Krasnow, J.D., as General Counsel". South San Francisco, CA & Paris....
• [2] Vifor Pharma AG. (12/14/21). "Press Release: CSL Limited Announces Tender Offer to Acquire Vifor Pharma Ltd (ad hoc)". St. Gallen....
• [3] Vifor Pharma AG. (11/09/20). "Press Release: Vifor Pharma and Angion Sign License Agreement for ANG-3777 in Nephrology Indications". St. Gallen & Uniondale, NY....
• [4] Vifor Pharma AG. (10/20/20). "Press Release: Vifor Pharma and Cara Therapeutics Sign US License Agreement for i.v. Korsuva to Treat Dialysis Patients with Pruritus". St. Gallen & Stamford, CT....
• [5] ChemoCentryx Inc.. (11/25/19). "Press Release: ChemoCentryx and VFMCRP Announce Positive Topline Data from Pivotal Phase III ADVOCATE Trial Demonstrating Avacopan’s Superiority Over Standard of Care in ANCA-Associated Vasculitis". Mountain View, CA & St...
• [6] Santhera Pharmaceuticals AG. (11/4/19). "Press Release: Santhera Appoints New Chief Executive Officer". Pratteln....
• [7] Laboratoris Sanifit S.L.. (7/17/18). "Press Release: Sanifit to Present at the 2018 European Biotech Investor Day in New York City". Palma & San Diego, CA....
• [8] Vifor Pharma AG. (5/23/18). "Press Release: VFMCRP and Cara Therapeutics to Develop and Commercialise CR845 Injection for Chronic Kidney Disease-associated Pruritus"....
• [9] Actimed Therapeutics Ltd.. (4/5/18). "Press Release: Actimed Therapeutics Appoints Pharma Veteran Dr David Ebsworth as Chairman". Ascot....
• [10] Laboratoris Sanifit S.L.. (3/6/18). "Press Release: Sanifit Announces Results of the Phase II Clinical Trial of SNF472 in Patients with Calciphylaxis". Palma & San Diego, CA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.